-
Yoshida,T., Akahoshi,F., Sakashita,H., Kitajima,H., Nakamura,M., Sonda,S., Takeuchi,M., Tanaka,Y., Ueda,N., Sekiguchi,S., Ishige,T., Shima,K., Nabeno,M., Abe,Y., Anabuki,J., Soejima,A., Yoshida,K., Takashina,Y., Ishii,S., Kiuchi,S., Fukuda,S., Tsutsumiuchi,R., Kosaka,K., Murozono,T., Nakamaru,Y., Utsumi,H., Masutomi,N., Kishida,H., Miyaguchi,I. and Hayashi,Y.
Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Bioorg Med Chem20, 5705-5719. PubMed Europe PubMed DOI I
2012
